Symbols

Symbols

ITRM

ITRM

Iterum Therapeutics Posts Q3 2025 Earnings: Launch Success and Financial Challenges

Iterum Therapeutics Q3 2025 Earnings Call: ORLYNVAH Sales Projected at $5M-$15M in 2026

Thursday Nov 13, 2025

Iterum Therapeutics shares rise 10.64% after-hours after FDA approval of ORLYNVAH and upcoming Q3 earnings report.

Friday Nov 07, 2025

Iterum Therapeutics to release Q3 2025 financial results Nov. 14.

Tuesday Oct 14, 2025

Iterum Presents 2 Posters at IDWeek 2025 Conference on UTI Treatment

Iterum Therapeutics to Present Data at IDWeek 2025 Conference

Saturday Sep 20, 2025

Iterum Therapeutics Sees Cash Runway Through 2026 with Antimicrobial Susceptibility Test Disc Clearance

Friday Aug 29, 2025

Iterum Therapeutics Faces Nasdaq Delisting Notice: A Critical Turning Point for the Company's Future

Wednesday Aug 20, 2025

Iterum Therapeutics Launches ORLYNVAH Antibiotic for UTIs

Iterum Therapeutics shares fall 10.11% intraday despite launching ORLYNVAH for uUTIs.

Iterum Therapeutics shares fall 5.42% intraday despite launching ORLYNVAH for uUTIs.

Iterum Therapeutics Launches ORLYNVAH, Oral Penem Antibiotic for UTIs.

Iterum Therapeutics launches ORLYNVAH for uncomplicated urinary tract infections.

Iterum Therapeutics Introduces ORLYNVAH™, the First Oral Penem Antibiotic for uUTIs in the U.S.

Tuesday Aug 12, 2025

Iterum Therapeutics Director Dunne Buys 15,000 Shares at $0.72/Share on Aug 8.

Thursday Aug 07, 2025

Iterum Therapeutics Reports Q2 2025 Results, Expects ORLYNVAH Launch

Iterum Therapeutics Extends Cash Runway to 2026 with $13M in Cash and $2.2M in Net Proceeds from ATM Offering.

Iterum Therapeutics' Q2 Earnings Call: Optimism Amid Challenges with ORLYNVAH Launch

Tuesday Aug 05, 2025

Iterum Therapeutics Q2 2025: Non-GAAP EPS Misses Estimate, R&D Expenses Down 48.2%

Iterum Aims for Early ORLYNVAH Launch in August 2025, Targets $40M uUTI Market